Why is "Phenylketonuria" trending?
Latest news, Wikipedia summary, and trend analysis.
Trend Analysis
- Ranking position: #
- Date: 2026-03-21 15:41:43
This topic has appeared in the trending rankings 1 time(s) in the past year. While it does not trend frequently, its appearance suggests a renewed or concentrated surge of public interest.
Based on Wikipedia pageviews and search interest, this topic gained significant attention on the selected date.
Trend Insight
This topic is not currently in the ranking.
Wikipedia Overview
Phenylketonuria (PKU) is an inborn error of metabolism that results in decreased metabolism of the amino acid phenylalanine. Untreated PKU can lead to intellectual disability, seizures, behavioral problems, and mental disorders. It may also result in a musty smell and lighter skin. A baby born to a mother who has poorly treated PKU may have heart problems, a small head, and low birth weight.
Read more on Wikipedia →Related Topics
Trending Topic Today
Search Interest Perspective
-
Impact of gut probiotic metabolites on phenylketonuria - Frontiers
-
Therapeutic effect of histone deacetylase 6 inhibitor for a mouse model of phenylketonuria - Nature
-
Phenylalanine in Foods and Drinks: What You Need to Know - Verywell Health
-
Otsuka Unveils New Repinatrabit Open-Label Extension Data in Phenylketonuria (PKU) Signaling Efficacy in Adolescents at the 2026 American College of Medical Genetics and Genomics (ACMG) Meeting - BioSpace
-
Skill Checkup: A Girl With Phenylketonuria - Medscape
-
Phenylketonuria Market to Reach New Heights by 2034, Driven by Innovative Therapies and Rising Diagnosis Rates | DelveInsight - PR Newswire
-
FDA Approves Sepiapterin for Adults, Children Living With Phenylketonuria - Pharmacy Times
-
Simplifying the diet for patients with phenylketonuria (PKU): unrestricted consumption of fruit and vegetables - ernaehrungs-umschau.de
-
FDA approves sepiapterin to treat phenylketonuria in adult, pediatric patients - Contemporary Pediatrics
-
Phenylketonuria (Pku): quality of life through integrated care pathways - Il Sole 24 ORE
-
Beam Therapeutics Reports Fourth Quarter and Year-End 2025 - GlobeNewswire
-
Docosahexaenoic acid supplementation in phenylketonuria: a systematic review - Frontiers
-
Unveiling the phenylalanine coaggregation mechanism for a deep understanding of phenylketonuria disease - Nature
-
U.S. Food and Drug Administration Approves BioMarin's PALYNZIQ® (pegvaliase-pqpz) for Adolescents 12 Years of Age and Older with Phenylketonuria (PKU) - PR Newswire
-
Genomic profiling, implications for genotype-based treatment of 131 patients with phenylketonuria and characterization of novel p.Pro416Leu PAH variant - Nature
-
Rethinking phenylalanine levels in phenylketonuria for optimal neurocognitive development beyond childhood - Frontiers
-
BioMarin Announces Positive Pivotal Phase 3 Data for PALYNZIQ® (pegvaliase-pqpz) in Adolescents with Phenylketonuria at 15th International Congress of Inborn Errors of Metabolism - PR Newswire
-
PTC Therapeutics Announces Approval of Sephience™ (sepiapterin) for the Treatment of Children and Adults Living with Phenylketonuria (PKU) in Japan - PR Newswire
-
Effects of exercise conducted prior to phenylketonuria-type meal on appetite, satiety hormones and energy expenditure: a randomised cross-over trial - Nature
-
FDA Accepts BioMarin's PALYNZIQ® (pegvaliase-pqpz) Supplemental Biologics License Application for Priority Review to Expand Use to Adolescents Aged 12-17 with Phenylketonuria - PR Newswire
-
Beam Designs New Approach for Direct Correction of Mutations Causing PKU - Genetic Engineering and Biotechnology News
-
Broad label FDA approval for phenylketonuria drug - European Pharmaceutical Review
-
Phenylketonuria Treatment Market Forecast Trends and Outlook 2025-2034 | Advancements in Treatment Options Likely to Augment Demand, Gene Therapy Advancements are Expected to Impact Market Landscape - finance.yahoo.com
-
When defining UMN, the EU must not leave phenylketonuria patients behind - Open Access Government
-
Germany will be first launch for PTC's phenylketonuria drug - pharmaphorum
-
Arla Foods Ingredients advances low-phenylalanine medical nutrition with Lacprodan CGMP-30 - Nutrition Insight
-
Stephanie Sacharow, MD, highlights the benefits of Palynziq to treat PKU - Contemporary Pediatrics
-
Maze Therapeutics Announces Positive First-in-Human Results from Phase 1 Trial of MZE782, Establishing Proof of Mechanism for a Potent, Oral SLC6A19 Inhibitor with Potential to Treat Phenylketonuria (PKU) and Chronic Kidney Disease (CKD) - finance.yahoo.com
-
Sibling-controlled study of the impact of dietary therapy on the gut microbiota in children with phenylketonuria - Frontiers
-
Phenylketonuria Clinical Trial Pipeline Appears Robust With 25+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight | DelveInsight - finance.yahoo.com
-
EU greenlights PTC's Sephience for phenylketonuria - FirstWord Pharma
-
PTC Therapeutics Announces Health Canada Approval of Sephience™ (sepiapterin) for the Treatment of Children and Adults Living with Phenylketonuria (PKU) - Newswire Canada
-
Pushing the Boundaries of Living with PKU: Karlye’s Story - biomarin.com
-
Infant and Maternal Health - National Institutes of Health (.gov)
-
Maze soars as early data back small molecule's potential in PKU, CKD - FirstWord Pharma
-
PTCT Gains Japanese Approval for Phenylketonuria Treatment - GuruFocus
-
PTC secures EC approval for Sephience to treat phenylketonuria - worldpharmaceuticals.net
-
The kids are alright: Old drug from BioMarin scores key win in teens - San Francisco Business Times - The Business Journals
-
Woman with Rare Metabolic Disorder Adopts Girl with the Same Disease: 'She's My Mini-Me' (Exclusive) - people.com
-
Rapid and definitive treatment of phenylketonuria in variant-humanized mice with corrective editing - Nature
-
BioMarin Axes Pre-Clinical PKU Drug, Citing Underwhelming Immunogenicity - BioSpace
-
Press Release, dated July 28, 2025 issued by PTC Therapeutics, Inc. - SEC.gov - SEC.gov
-
Development of a synthetic live bacterial therapeutic for the human metabolic disease phenylketonuria - Nature
-
Improvement of a synthetic live bacterial therapeutic for phenylketonuria with biosensor-enabled enzyme engineering - Nature
-
Joyanna Hansen: A Journey from the Clinic to BioMarin - biomarin.com
-
Phenylketonuria: Giving treatment a second chance - Boston Children's Answers
-
FDA accepts pegvaliase-pqpz sBLA to expand treatment to patients with PKU aged 12-17 years - Contemporary Pediatrics
-
BioMarin drops preclinical PKU drug once seen as potential Palynziq successor - Fierce Biotech
-
A new CRISPR startup is betting regulators will ease up on gene-editing - technologyreview.com
-
Psychiatric and Cognitive Aspects of Phenylketonuria: The Limitations of Diet and Promise of New Treatments - Frontiers
-
PKU and the pediatrician with Suzanne Hollander, MS, RD, LDN - Contemporary Pediatrics
-
U.S. Food and Drug Administration Approves BioMarin's PALYNZIQ® (pegvaliase-pqpz) for Adolescents 12 Years of Age and Older with Phenylketonuria (PKU) - Finansavisen
-
BioMarin (NASDAQ: BMRN) PALYNZIQ sBLA gets FDA Priority Review to expand to ages 12–17 - Stock Titan
-
At the Bedside: Houston Man Achieving Bucket List Dream After Game-Changing Rare Disease Care at UTHealth Houston | Newswise - Newswise
-
FDA approves PTC Therapeutics’ Sephience to treat rare metabolic disorder PKU - PMLiVE
-
Efficacy and safety of a synthetic biotic for treatment of phenylketonuria: a phase 2 clinical trial - Nature
-
Researchers discover new factor in preventing phenylketonuria, offering new treatment strategy - UT MD Anderson
-
Sapropterin (KUVAN) Comprehensive Forecast on - openPR.com
-
CRISPR/Cas9 generated knockout mice lacking phenylalanine hydroxylase protein as a novel preclinical model for human phenylketonuria - Nature
-
Tetrahydrobiopterin as an Alternative Treatment for Mild Phenylketonuria - NEJM
-
Discovery of a New Structural Variant of the PAH Gene Associated with Phenylketonuria (PKU) in Chile - Universidad de Chile
-
Genetics of Phenylketonuria: Then and Now - Blau - 2016 - Human Mutation - Wiley Online Library
-
Improved specificity and efficiency of in vivo adenine base editing therapies with hybrid guide RNAs - Nature
-
Treatment of a metabolic liver disease in mice with a transient prime editing approach - Nature
-
Campfires and Connections: How Summer Camp Brings Families with PKU Together - biomarin.com
-
How phenylketonuria, a once-neglected disease, became a proving ground for new drugs - C&EN
-
PKU and sepiapterin data with Suzanne Hollander, MS, RD, LDN - Contemporary Pediatrics
-
Characterizing the mechanism of action for mRNA therapeutics for the treatment of propionic acidemia, methylmalonic acidemia, and phenylketonuria - Nature
-
PTC To Challenge BioMarin In PKU With Oral Sephience - Citeline News & Insights
-
Discovery offers new treatment strategy for phenylketonuria - National Science Foundation (.gov)
-
Blood phenylalanine reduction reverses gene expression changes observed in a mouse model of phenylketonuria - Nature
-
Sepiapterin: a potential new therapy for phenylketonuria - The Lancet
-
Development of a mechanistic model to predict synthetic biotic activity in healthy volunteers and patients with phenylketonuria - Nature
-
BioMarin Announces Positive Pivotal Data for PALYNZIQ® (pegvaliase-pqpz) in Adolescents with Phenylketonuria - PR Newswire
-
Aurora Therapeutics launches to develop CRISPR therapies for rare diseases - C&EN
-
Neonatal diagnosis is key in patients with phenylketonuria (PKU) - Hospital Clínic Barcelona
-
BioMarin’s trial for phenylketonuria therapy meets primary efficacy endpoint - Clinical Trials Arena
-
Long-term treatment of phenylketonuria with a new medical food containing large neutral amino acids - Nature
-
Aurora sets out to capitalize on FDA’s new framework for bespoke drug therapies - BioPharma Dive
-
Molecular characterization of phenylketonuria and tetrahydrobiopterin-responsive phenylalanine hydroxylase deficiency in Japan - Nature
-
Orsini Selected as Specialty Pharmacy Partner for PTC Therapeutics' SEPHIENCE™ (sepiapterin) - PR Newswire
-
BioMarin Announces Positive Pivotal Phase 3 Data for PALYNZIQ® (pegvaliase-pqpz) in Adolescents with Phenylketonuria at 15th International Congress of Inborn Errors of Metabolism - Finansavisen
-
Characterization of an engineered live bacterial therapeutic for the treatment of phenylketonuria in a human gut-on-a-chip - Nature
-
Dietary intake and nutritional status of patients with phenylketonuria in Taiwan - Nature
-
FDA Accepts BioMarin's PALYNZIQ® (pegvaliase-pqpz) Supplemental Biologics License Application for Priority Review to Expand Use to Adolescents Aged 12-17 with Phenylketonuria - Finansavisen
-
Recent Advances in Phenylketonuria: A Review - Cureus
-
US FDA Approves PTC Therapeutics' Metabolic Disorder Drug - U.S. News & World Report
-
Charlie’s journey from diagnosis at 10 days old to happy, healthy toddler - The Impartial Reporter
-
PTC's PKU drug scores US approval - FirstWord Pharma
-
Phenylalanine Effects on Brain Function in Adult Phenylketonuria - Neurology® Journals
-
Maze’s MZE782 Shows Positive Results for PKU, CKD in Trial - The Clinical Trial Vanguard
-
Maze reports positive results from Phase I trial of PKU and CKD treatment - Clinical Trials Arena
-
Phenylalanine assembly into toxic fibrils suggests amyloid etiology in phenylketonuria - Nature
-
BioMarin's Palynziq excels in late-stage phenylketonuria study for adolescents - FirstWord Pharma
-
From Lab to Life: CRISPR's Advancements in Personalized Therapies for Metabolic, Blood, and Other Disorders - ISAAA
-
Intrinsic property of phenylalanine to trigger protein aggregation and hemolysis has a direct relevance to phenylketonuria - Nature
-
CRISPR RNA-guided FokI nucleases repair a PAH variant in a phenylketonuria model | Scientific Reports - Nature
-
Phenylketonuria Market Size & Trends Report by 2032 - Straits Research
-
Aurobindo launches sapropterin dihydrochloride tablets - Drug Store News
-
New biosensors help control phenylketonuria disease | LABPATCH Project | Results in Brief | H2020 - CORDIS
Why This Topic Is Trending
This topic has recently gained attention due to increased public interest. Search activity and Wikipedia pageviews suggest growing global engagement.
Search Interest & Related Topics
Search interest data over the past 12 months indicates that this topic periodically attracts global attention. Sudden spikes often correlate with major news events, public statements, or geopolitical developments.